From Yahoo Finance: 2025-06-20 15:00:00

Eli Lilly (LLY) is a pharmaceutical company that focuses on various health sectors, such as cardiometabolic, neuroscience, oncology, and immunology. Founded in 1876, the company operates in 125 countries. The stock has shown recent volatility, gaining 2.3% in the past month but down 1% year-to-date and 21.4% below its 52-week high.

In the first quarter, Eli Lilly reported a profit of $3.34 per adjusted share, surpassing $12.73 billion in revenue, a 45% increase year-over-year. Revenue from Mounjaro rose 113% to $3.84 billion, with Zepbound generating $2.31 billion, up 20.9%.

Investors reacted negatively to the results, causing Eli Lilly’s shares to drop over 11% as the company revised its profit forecast due to heightened acquired research and development charges. The adjusted EPS guidance was lowered to $20.78-$22.28 from $22.50-$24.00 per share.

Eli Lilly has announced a $1.3 billion acquisition of gene-editing company Verve Therapeutics, valuing it at $10.50 per share, a 67.5% premium to its pre-announcement price. This acquisition aims to diversify Eli Lilly’s operations beyond diabetes and weight-loss drugs.

Verve Therapeutics’ gene-editing technology focuses on lowering cholesterol levels in cardiovascular patients by deactivating genes like PCSK9, LPA, and ANGPTL3. The company is currently in early-stage clinical trials for patients with genetic disorders causing high LDL cholesterol levels.

Eli Lilly is highly rated as a pharmaceutical stock, with a consensus “Strong Buy” rating and a mean price target of $983.12, indicating nearly 29% upside potential. Twenty-six analysts cover the stock, with 20 “Strong Buy,” two “Moderate Buy,” and four “Hold” ratings from Wall Street.



Read more at Yahoo Finance: A $1.3 Billion Reason to Buy Eli Lilly Stock Now